Recently, RIPK1 activation was described in human COVID-19 lung samples; inhibition of RIPK1 with the use of small molecules reduced lung viral load and mortality in ACE2 transgenic mice (69, 88). The gene discussed is RIPK1; the disease is COVID-19.